drugset / Trial / NCT00034203

Safety and Efficacy of a Monoclonal Antibody for Treatment of Rheumatoid Arthritis.

NCT00034203

Phase 2 Completed XOMA (US) LLC
RandomizedDouble-blindTreatment

Summary

The purpose of this study is to determine whether a humanized monoclonal antibody (efalizumab) is safe and effective in the treatment of rheumatoid arthritis.

Timeline

Start
2002-04
Primary completion
Completion
2003-08

Drugs

EvaluationDrugModalityDoseRoute
Subject efalizumab Monoclonal antibody

Indications